As a result of the outcomes of a trial comparing two drug-coated balloon (DCB) devices, in which no statistically significant patency rate difference was found, data and analytics company, GlobalData, has indicated a potential change in the competitive landscape in this market sector.
Competition
Drug-coated balloons, also known as drug-eluting balloons, are used as a therapeutic alternative to de novo angioplasty. They work by delivering an antirestenotic drug (one that widens the arteries to prevent restenosis) to the vessel wall once inflation has occurred.